TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One of the following Biopsy-confirmed, aggressive non-Hodgkin's lymphoma~  1. Diffuse large B-cell lymphoma~ 2. Mediastinal (thymic) B-cell lymphoma~* Any stage (I through IV) as defined by the Ann Arbor staging system~* ECOG performance status of 0 to 2~* Radiographically measurable disease~* No more than 3 cycles of chemotherapy for lymphoma~* Greater than or equal to 18 years~* Adequate pulmonary, cardiac, hepatic, or renal function~* HIV antibody negative~* Women- Not pregnant or breastfeeding~* Men of reproductive potential must agree to use contraception~Exclusion Criteria:~* Patients with the following aggressive lymphomas are not eligible:~  1. Mantle cell~ 2. Lymphoblastic~ 3. Burkitt's~ 4. Mycosis fungoides/Sezary's syndrome~ 5. HTLV-1 associated T-cell leukemia/lymphoma~ 6. Primary CNS lymphoma~ 7. HIV-associated lymphoma~ 8. Transformed lymphomas~ 9. Immunodeficiency-associated lymphomas~* Previous diagnosis of another hematologic malignancies~* Progressive disease on CHOP or Rituximab-CHOP~* Active CNS involvement by lymphoma~* Serious co-morbid disease that could preclude full participation in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET Negative (Type: ACTIVE_COMPARATOR): R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
- PET Positive (Type: ACTIVE_COMPARATOR): R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early FDG PET in Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, at least 18 years of age~* History of histologically confirmed melanoma as assessed per medical record review.~* Eligible for the trial UPCC #01615, A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma.~* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~* Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.~* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.~* Ineligible for the trial UPCC #01615, A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma.~* Only individuals (aged 18 or over) who can understand and give informed consent will be eligible to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Children, fetuses, neonates, or prisoners are not included in this research study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): FDG PET/CT scan pre-therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin for the Treatment of Vulvodynia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women age 18 or greater~* Vulvodynia as defined as chronic vulvar discomfort or pain, characterized by burning, stinging, irritation or rawness of the female genitalia in cases in which there is no infection or skin disease of the vulva or vagina causing these symptoms. Pain may be constant or intermittent, localized or diffuse. Symptoms may be consistent with either Generalized Vulvodynia (diffuse or focal and constant or unremitting symptoms present in the labia majora, labia minora, and/or the vestibule that are not necessarily caused by touch or pressure to the vulva) or Vulvar Vestibulitis Syndrome (pain only in the vestibule and only during or after touch or pressure is applied).~* Pain ≥ 40 on 100mm VAS~* Practicing reliable form of birth control defined as sterilization, hormonal contraception, abstinence, IUD~* Must be able to attend follow up visits and are not likely to leave the area during the study period~Exclusion Criteria:~* Atrophic vaginitis, active bacterial vaginosis, yeast, and herpetic infections~* Current pregnancy diagnosed by positive serum or urine pregnancy test~* Current breastfeeding~* Seizure disorder or other chronic neurologic disease~* Diagnosis of chronic renal insufficiency defined as creatinine \>1.4~* Unable to read and speak English~* Contraindication to pregabalin or history of prior use of pregablin~* Chronic narcotic or benzodiazepine use~* Chronic alcohol abuse~* Other chronic pain disorders, (ie. chronic pelvic pain, endometriosis, interstitial cystitis)~* Chronic neuropathic pain or anything affecting sensation (ie. MS, stroke)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pregabalin/placebo (Type: EXPERIMENTAL): pregabalin and placebo given using a cross-over design
- placebo/pregabalin (Type: EXPERIMENTAL): placebo and pregabalin given using a cross-over design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available~* Performance Status of 0 or 1~* Adequate bone marrow, kidney and liver function~* Part 2 includes target expressing NSCLC, ovarian or breast cancer patients~Exclusion Criteria:~* Brain metastases requiring steroids~* Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas)~* Active and clinically significant bacterial, fungal, or viral infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06664178 (Type: EXPERIMENTAL): Experimental

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Radiotherapy for Rectal Cancer Using the Photon Radiosurgery System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Operable rectal cancer~Exclusion Criteria:~* Locally advanced disease requiring long course pre-operative chemoradiation, metastatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12 Gray IORT (Type: EXPERIMENTAL): None
- 15 Gray IORT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of systemic juvenile idiopathic arthritis as per ILAR definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age:~   * Arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following:~  * evanescent nonfixed erythematous rash,~  * generalized lymph node enlargement,~  * hepatomegaly and/ or splenomegaly,~  * serositis~2. Parent's or legal guardian's written informed consent and child's assent, if appropriate, or patient's informed consent for ≥ 18 years of age~3. Male and female patients aged ≥ 2 to \< 20 years of age~4. Active disease at the time of enrollment defined as follows:~   * At least 2 joints with active arthritis~  * Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening period within 1 week before first canakinumab/placebo dose~  * C-reactive protein (CRP) \> 30 mg/L (normal range \< 10 mg/L)~5. Naïve to canakinumab~6. Other protocol defined inclusion criteria may apply~Exclusion Criteria:~Patients who fulfilled one or more of the following criteria were not eligible for inclusion in this study:~1. Pregnant or nursing (lactating) female patients~2. Female patients having reached sexual maturity unless their career, lifestyle, or sexual orientation precluded intercourse with a male partner and/or they were using an acceptable method of contraception~3. History of hypersensitivity to study drug or to biologics.~4. Diagnosis of active macrophage-activation syndrome (MAS) (Ravelli, Magni-Manzoni and Pistorio 2005) within the last 6 months~5. With active or recurrent bacterial, fungal or viral infection, including patients with evidence of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C infection~6. Other protocol defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\>37.5 kg) received two sc injections.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received a single dose matching placebo of canakinumab on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 29 days-3 months~* Minimum Body weight 3.0 kg~* Indications: septical work up~* Parent has been informed about the study and has signed Informed Consent Form~Exclusion Criteria:~* Infants who were born prematurely (before 37 weeks gestation)~* Known kidney or liver disease~* Known chronic illness~* Documented previous adverse reaction to nalbuphine~* Treatment with a depressant drug within 5 days prior to study~* Epistaxis, nose trauma (only for the intranasal application)~* Barriere of language

- Gender: ALL
- Minimum Age: 29 Days
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- intravenous (Type: ACTIVE_COMPARATOR): single iv application of nalbuphine 0.05mg/kg
- intranasal (Type: ACTIVE_COMPARATOR): single intranasal application of nalbuphine 0.1mg/kg in infants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical signs and symptoms of primary VL (fever for at least 2 weeks, splenomegaly) and diagnosis confirmed by visualization of parasites in tissue samples (lymph node, bone marrow) on microscopy.~* Patients aged between 15 and 60 years (inclusive) who are able to comply with the protocol.~* Patients for whom written informed consent has been signed by the patients themselves (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18 years of age together with the patients assent.~* HIV negative status~Exclusion Criteria:~* Patients who have previously been diagnosed with VL and received anti-leishmanial treatment (ie relapse)~* Patients with BMI \<16 kg/m2~* Patients with contra-indication (known hypersensitivity) to other imidazoles (e.g. ketaconazole)~* Patients suffering from a concomitant severe underlying disease (cardiac, renal, hepatic) including hepatitis B, para kala-azar dermal leishmaniasis and tuberculosis~* Patient with clinically significant ECG findings or QTcF≥ 450 msec in 2 successive ECGs~* Major surgical intervention 4 weeks prior to enrollment.~* Patients who are pregnant or lactating.~* Female patients of child bearing age who do not agree to use an acceptable method of contraception~* Patients with haemoglobin \< 5g/dl.~* Patients with platelets \< 40,000/mm³.~* Patients with liver function (ALT and AST) tests of more than 2 times the upper limit of the normal range.~* Patients with serum creatinine above the normal range for age and gender.~* Patients with serum potassium (K+) above the normal range~* Patients with Bilirubin more than 1.5 times the upper limit of the normal range

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fexinidazole (Type: EXPERIMENTAL): 600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Transitional cell carcinoma of the bladder with biopsy proven muscle invasion suitable for resection leaving no residual visible or palpable tumor mass Unifocal No greater than 5 cm Stages II and III (T2-T3a, N0-NX, M0) No prior treatment for bladder cancer other than endoscopic resection, intravesical chemotherapy, or intravesical immunotherapy~PATIENT CHARACTERISTICS: Age: Not specified Performance status: WHO 0-1 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 120,000/mm3 Hepatic: Bilirubin normal SGOT/SGPT normal Renal: GFR at least 50 mL/min Cardiovascular: Normal cardiac function (i.e., no New York Heart Association class II-IV) Other: Normal auditory function No second primary malignant tumor except basal cell carcinoma of the skin Fit for cisplatin containing combination chemotherapy, radical radiotherapy, or cystectomy No active infections Not pregnant or nursing No concurrent illness that significantly affects clinical assessments~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics No prior systemic chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the bladder Surgery: See Disease Characteristics No prior partial cystectomy Prior transurethral resection of the bladder allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* renal transplant recipient at least 3 months post transplant~* hypercalcemia~* hyperparathyroidism~Exclusion Criteria:~* allergic to cinacalcet, tetracycline.~* pregnancy~* on medication that utilize same liver system as cinacalcet Hcl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet HCl (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 18 and 75 years of age, inclusive;~* With a diagnosis of ileal or ileo-colonic Crohn's disease for a minimum of 3 months prior to inclusion;~* An ileocolonoscopy scheduled prior to study inclusion;~* Agreeing to participate and to sign an informed consent form;~* Able to perform stool collection, at home, according to protocol;~* Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research.~Exclusion Criteria:~* Colonic Crohn's disease of L2 phenotype based on Montreal classification;~* Extensive small bowel resection (\> 100 cm) or short bowel syndrome~* Bowel strictures/stenosis contraindicating ilecolonoscopy;~* Currently with an ostomy or an ileoanal pouch;~* Currently receiving total parenteral nutrition;~* Bowel preparation received in the previous 3 months;~* An increased risk of hemorrhage (patients with anticoagulant/antiplatelet therapy)~* History of intestinal carcinoma and colorectal cancer;~* History or presence of alcohol or substance abuse;~* History of chronic uncontrolled disorders;~* Current participation in an investigational product trial;~* Less than 4 weeks since last participation in a clinical trial;~* Subject inapt or unwilling to participate to the study;~* Pregnant or breastfeeding mother;~* Patient under guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single-arm study (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tight Glycaemic Control During Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \> 15 years~* cardiac surgery with cardiopulmonary bypass~Exclusion Criteria:~* active infection~* insulin allergy~* off-pump cardiopulmonary bypass procedures

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tight glycaemic control (TGC) (Type: EXPERIMENTAL): TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
- Conventional glycaemic control (Control) (Type: PLACEBO_COMPARATOR): Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues